Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Soleno Therapeutics ( (SLNO) ) has issued an update.
On its February 25, 2026 earnings call, Soleno announced that veteran pharmaceutical finance executive Jennifer Fulk will become chief financial officer on March 2, 2026, succeeding long-time CFO James Mackaness, who plans to retire by the end of March. Fulk’s compensation package includes a $525,000 base salary, performance-based bonus eligibility, and equity grants, underscoring her strategic role as Soleno scales its rare-disease franchise.
Mackaness will remain with the company as an at-will employee until March 31, 2026 and then as a consultant through year-end, providing continuity in financial leadership as Soleno navigates its commercial expansion and ongoing capital markets engagement. The leadership transition pairs Fulk’s extensive experience at Eli Lilly, Talkspace and 120Water with Soleno’s growth trajectory following the U.S. launch of VYKAT XR, aiming to support operational efficiency and long-term value creation for stakeholders.
The most recent analyst rating on (SLNO) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Soleno Therapeutics stock, see the SLNO Stock Forecast page.
Spark’s Take on SLNO Stock
According to Spark, TipRanks’ AI Analyst, SLNO is a Neutral.
The score is driven primarily by the sharp 2025 financial turnaround (revenue scale, profitability, positive free cash flow) and a strong low-debt balance sheet. These positives are tempered by weak technical trend/momentum and limited valuation support due to a negative P/E and no dividend, while the latest earnings call was constructive but flagged launch friction from discontinuations and short-seller-related disruption.
To see Spark’s full report on SLNO stock, click here.
More about Soleno Therapeutics
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets for hyperphagia in adults and children with Prader-Willi syndrome, was approved by the U.S. Food and Drug Administration on March 26, 2025. Soleno is currently rolling out VYKAT XR in the U.S. market and pursuing regulatory approvals in additional territories.
On its February 25, 2026 earnings call, Soleno announced that veteran pharmaceutical finance executive Jennifer Fulk will become chief financial officer on March 2, 2026, succeeding long-time CFO James Mackaness, who plans to retire by the end of March. Fulk’s compensation package includes a $525,000 base salary, performance-based bonus eligibility, and equity grants, underscoring her strategic role as Soleno scales its rare-disease franchise. Mackaness will remain with the company as an at-will employee until March 31, 2026 and then as a consultant through year-end, providing continuity in financial leadership as Soleno navigates its commercial expansion and ongoing capital markets engagement.
Average Trading Volume: 1,463,241
Technical Sentiment Signal: Sell
Current Market Cap: $2.1B
Find detailed analytics on SLNO stock on TipRanks’ Stock Analysis page.